Beyond lung and thyroid cancer, a recent case reported a patient with RET fusion-positive pleiomorphic sarcoma that responded to a neoadjuvant RET inhibitor and that the neoadjuvant reduction in tumor glucose activity and size was assessed by FDG PET [18]. This evidence concerns the gene RET and neoplasm.